Pancreatic Cancer Research

ResearcherUniversität UlmActive in the last 2 years

Alexander Kleger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0592-5232; OpenAlex author ID A5055082801, A5068939051, A5073902397. Sources: OpenAlex.

Their work

Papers
39 (first author 2, last author 17)
Trials
0
Grants
0
Labs led
1
Collaborators
148
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 4 papers · 2021: 6 papers · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 7 papers · 2026: 5 papers

Papers 39

  1. DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer. Last author DOI 10.1002/advs.202417606↗
  2. A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-026-48584-2↗
  3. Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.09.027↗
  4. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-26-0138↗
  5. An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. Last author DOI 10.1186/s12943-025-02541-1↗
  6. Organoid-based precision medicine in pancreatic cancer. Last author DOI 10.1002/ueg2.12701↗
  7. Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy. Co-author DOI 10.1002/ueg2.12773↗
  8. Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies. Co-author DOI 10.1016/j.addr.2025.115697↗
  9. Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution Last author DOI 10.1101/2025.04.24.650216↗
  10. Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines. Co-author DOI 10.1136/jitc-2024-010579↗
  11. Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report. Co-author DOI 10.1159/000545975↗
  12. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. Co-author DOI 10.1186/s12943-025-02406-7↗
  13. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
  14. A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing. Co-author DOI 10.1038/s41598-024-60107-5↗
  15. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  16. The application of pancreatic cancer organoids for novel drug discovery. Last author DOI 10.1080/17460441.2023.2194627↗
  17. State-matched organoid models to fight pancreatic cancer. Last author DOI 10.1016/j.trecan.2022.03.003↗
  18. Editorial: Multimodality Treatment in Pancreatic Ductal Adenocarcinoma - Current Options and the Future Impact of Molecular Biological Profiling. First author DOI 10.1159/000521419↗
  19. Discussion: Current Multimodality Treatment Options in Pancreatic Cancer in Clinical Practice - What Is the Future Impact of Molecular Biological Profiling? Co-author DOI 10.1159/000521847↗
  20. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  21. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Last author DOI 10.1136/gutjnl-2019-319970↗
  22. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Last author DOI 10.1136/gutjnl-2019-319984↗
  23. RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-20-2633↗
  24. A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Last author DOI 10.3390/cancers13112539↗
  25. Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. Co-author DOI 10.3390/cancers13133145↗
  26. A feedback-loop between telomerase activity and stemness factors regulates PDAC stem cells Co-author DOI 10.1101/2020.11.02.361931↗
  27. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. Last author DOI 10.1177/2050640620905183↗
  28. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. Last author DOI 10.3390/cells9092110↗
  29. An Immunological Glance on Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ijms21093345↗
  30. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  31. Organoidomics - falling star or new galaxy in pancreatic cancer? First author DOI 10.1038/s41575-018-0052-3↗
  32. Precision medicine meets the DNA damage response in pancreatic cancer. Last author DOI 10.18632/oncoscience.392↗
  33. Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. Co-author DOI 10.18632/oncotarget.23330↗
  34. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Last author DOI 10.1158/0008-5472.can-17-0634↗
  35. Tbx3 fosters pancreatic cancer growth by increased angiogenesis and activin/nodal-dependent induction of stemness. Co-author DOI 10.1016/j.scr.2016.08.007↗
  36. Developmental Pathways Direct Pancreatic Cancer Initiation from Its Cellular Origin. Co-author DOI 10.1155/2016/9298535↗
  37. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Last author DOI 10.1038/ncomms8677↗
  38. Smarter drugs emerging in pancreatic cancer therapy. Co-author DOI 10.1093/annonc/mdu013↗
  39. Absence of FLICE-inhibitory protein is a novel independent prognostic marker for very short survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31829655ed↗

Closest collaborators

The 25 strongest of 148 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thomas Theodor Werner Seufferlein · 28 shared papers, 2014–2026 · strength 3.97
  2. Johann Gout · 13 shared papers, 2018–2026 · strength 2.21
  3. Élodie Roger · 12 shared papers, 2020–2026 · strength 2.19
  4. Lukas Perkhofer · 16 shared papers, 2014–2026 · strength 1.88
  5. Frank Arnold · 10 shared papers, 2020–2026 · strength 1.30
  6. Michael Karl Melzer · 6 shared papers, 2020–2026 · strength 1.24
  7. Thomas Jens Ettrich · 9 shared papers, 2018–2025 · strength 1.22
  8. Dharini Srinivasan · 5 shared papers, 2025–2026 · strength 1.14
  9. Anton Lahusen · 5 shared papers, 2024–2026 · strength 1.08
  10. Alica K. Beutel · 7 shared papers, 2019–2025 · strength 1.08
  11. Marko Kornmann · 7 shared papers, 2013–2025 · strength 1.02
  12. Tim Eiseler · 5 shared papers, 2016–2026 · strength 0.90
  13. Patrick Christian Hermann · 7 shared papers, 2016–2026 · strength 0.80
  14. Chantal Allgöwer · 4 shared papers, 2024–2026 · strength 0.78
  15. Karolin Walter · 7 shared papers, 2016–2026 · strength 0.72
  16. Christopher J. Halbrook · 3 shared papers, 2025–2026 · strength 0.62
  17. Pierre‐Olivier Frappart · 7 shared papers, 2017–2021 · strength 0.60
  18. Bruno Sáinz · 5 shared papers, 2020–2026 · strength 0.58
  19. Elisabeth Heßmann · 5 shared papers, 2015–2026 · strength 0.50
  20. Hans Armin Kestler · 4 shared papers, 2021–2025 · strength 0.47
  21. Yuan‐Na Lin · 2 shared papers, 2024–2025 · strength 0.47
  22. Anton Wellstein · 2 shared papers, 2024–2025 · strength 0.47
  23. Yazid J. Resheq · 2 shared papers, 2023–2025 · strength 0.45
  24. Martin Müller · 5 shared papers, 2016–2021 · strength 0.43
  25. Kanishka Tiwary · 3 shared papers, 2020–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.